Stay updated on Pembrolizumab in cSCC: Recurrent/Metastatic Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in cSCC: Recurrent/Metastatic Clinical Trial page.

Latest updates to the Pembrolizumab in cSCC: Recurrent/Metastatic Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe page footer now displays Revision: v3.4.3, replacing Revision: v3.4.2.SummaryDifference0.0%

- Check17 days agoNo Change Detected
- Check32 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2 with no visible changes to study content or layout. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check39 days agoChange DetectedRevision tag updated to v3.4.1, replacing v3.4.0, with no changes to study content or user-facing details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check61 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4.SummaryDifference0.0%

- Check83 days agoChange DetectedThe page's Locations section was reorganized into a single 'Locations' block with an expanded list of sites across multiple regions, replacing the prior country/state location headers. The update also includes Revision: v3.3.3.SummaryDifference2%

- Check113 days agoChange DetectedPublications section updated with clarifications that publications are provided voluntarily by the study entry author and are auto-filled from PubMed; the Revision: v3.3.2 note is now shown.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in cSCC: Recurrent/Metastatic Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in cSCC: Recurrent/Metastatic Clinical Trial page.